Mizuho Securities analyst Salim Syed has maintained their bullish stance on BBIO stock, giving a Buy rating today. Salim Syed’s rating ...

Product launches is the main strategy followed by the manufacturers for insect cell lines market. On March 2020, Lonza has ...

Acquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations New OPGx-LCA5 Phase 1/2 6-month data demonstrate sa ...

Dyno founder and CEO Eric Kelsic stated: “This new collaboration with Roche, focused on developing next-generation gene ...

Medera Inc. today announced that its clinical-stage gene therapy subsidiary, Sardocor Corp., has successfully completed its ...

Privately held Dyno Therapeutics Inc. has added another notch to its adeno-associated virus (AAV) vectors development ...

Roche will use Dyno’s technology, through which Dyno applies AI and high-throughput in vivo data collection to engineering ...

George Church-founded Dyno Therapeutics Inc. is adding to its list of pharma deals by signing a second research collaboration ...

Our heart muscle is studded with tiny dyads, intricately designed structures that manage incoming electrical signals and ...

Pharma presented positive preliminary data from eleven participants dosed in the CANaspire Phase 1/2 clinical trial of ...

The combined company, which will be called Opus Genetics, will focus on advancing a pipeline of gene therapies for inherited retinal diseases.

After forming a gene therapy partnership with Dyno Therapeutics in 2020, Roche is back for more. | In a new deal potentially ...